This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Adrafinil
A prodrug of modafinil that converts to its active form in the liver - provides similar wakefulness-promoting and cognitive-enhancing effects without requiring a prescription in most countries.
Benefits
What is Adrafinil?
Adrafinil is a synthetic eugeroic (wakefulness-promoting agent) first discovered in 1974 by scientists at the French pharmaceutical company Laboratoire Lafon. It was marketed in France as Olmifon for the treatment of narcolepsy and age-related cognitive decline before being voluntarily discontinued in 2011. Adrafinil is a prodrug - it is metabolised in the liver into modafinil, which is the actual active compound responsible for its cognitive effects.
The key distinction between adrafinil and modafinil is regulatory: modafinil is a prescription-only controlled substance in the UK and most countries, while adrafinil remains unscheduled and available as a supplement in many jurisdictions. A 1990 study published in Psychopharmacology demonstrated that adrafinil improved learning performance and reduced errors in aged beagle dogs over a 10-month treatment period. Human clinical trials in elderly patients with attention and memory difficulties showed significant improvements in alertness, attention, and psychomotor performance compared to placebo. Once converted to modafinil in the liver, it produces wakefulness primarily through histaminergic activation in the tuberomammillary nucleus and orexin/hypocretin system stimulation, with secondary effects on dopamine, norepinephrine, and glutamate neurotransmission. The onset is slower than modafinil (60-90 minutes vs 30-60 minutes) due to the hepatic conversion step.
- Hepatic conversion to modafinil: Metabolised by liver enzymes into modafinil and modafinilic acid. Modafinil is the primary active metabolite responsible for cognitive effects
- Histaminergic activation: Increases histamine release in the tuberomammillary nucleus, promoting wakefulness without the peripheral stimulation of amphetamines
- Orexin system stimulation: Activates orexin/hypocretin neurons in the hypothalamus, stabilising the sleep-wake cycle and maintaining sustained alertness
- Dopamine reuptake inhibition: Weakly inhibits dopamine transporter (DAT), increasing dopamine availability in the prefrontal cortex for improved executive function
- Glutamate enhancement: Increases glutamatergic transmission while reducing GABAergic tone, shifting the brain towards a more alert and engaged state
- Standard dosage: 300-600 mg per day, taken in the morning
- Conversion ratio: Approximately 300 mg adrafinil produces effects equivalent to 100 mg modafinil, though conversion efficiency varies between individuals
- Onset: 60-90 minutes (slower than modafinil due to hepatic conversion)
- Duration: Effects last approximately 8-12 hours. Avoid afternoon dosing to prevent sleep disruption
- Cycling recommended: Due to liver metabolism concerns, limit use to 2-3 times per week rather than daily. Consider periodic liver function monitoring with regular use
- Liver stress: Unlike modafinil (which bypasses significant liver metabolism), adrafinil places additional load on the liver during conversion. Regular liver function tests are recommended with sustained use
- Hepatotoxicity risk: Rare but documented cases of elevated liver enzymes. Avoid in individuals with pre-existing liver conditions or heavy alcohol use
- Skin reactions: Rare risk of Stevens-Johnson syndrome and DRESS syndrome, shared with modafinil. Discontinue immediately if skin rash develops
- Cardiovascular: May increase heart rate and blood pressure modestly. Use with caution in individuals with cardiovascular conditions
- Drug interactions: Metabolised by CYP3A4. May interact with hormonal contraceptives, warfarin, and other CYP3A4 substrates. Consult your doctor if taking medications
Natural Sources & Forms
- Powder: Available from nootropic supplement vendors as bulk powder for flexible dosing
- Capsules: Pre-dosed capsules (300 mg) available from specialist nootropic retailers
- Legal note: Unscheduled in the UK and US (not a controlled substance), though not approved as a medicine. Modafinil itself requires a prescription
Frequently Asked Questions
A prodrug of modafinil that converts to its active form in the liver - provides similar wakefulness-promoting and cognitive-enhancing effects without requiring a prescription in most countries.
The key benefits of Adrafinil include: Cognitive Enhancement, Energy, Focus, Memory, Mood, Motivation.
Hepatic conversion to modafinil: Metabolised by liver enzymes into modafinil and modafinilic acid. Modafinil is the primary active metabolite responsible for cognitive effects Histaminergic activation: Increases histamine release in the tuberomammillary nucleus, promoting wakefulness without the peripheral stimulation of amphetamines Orexin system stimulation: Activates orexin/hypocretin neurons in the hypothalamus, stabilising the sleep-wake cycle and maintaining sustained alertness Dopamine reuptake inhibition: Weakly inhibits dopamine transporter (DAT), increasing dopamine availability in the prefrontal cortex for improved executive function Glutamate enhancement: Increases glutamatergic transmission while reducing GABAergic tone, shifting the brain towards a more alert and engaged state
Standard dosage: 300-600 mg per day, taken in the morning Conversion ratio: Approximately 300 mg adrafinil produces effects equivalent to 100 mg modafinil, though conversion efficiency varies between individuals Onset: 60-90 minutes (slower than modafinil due to hepatic conversion) Duration: Effects last approximately 8-12 hours. Avoid afternoon dosing to prevent sleep disruption Cycling recommended: Due to liver metabolism concerns, limit use to 2-3 times per week rather than daily. Consider periodic liver function monitoring with regular use
Liver stress: Unlike modafinil (which bypasses significant liver metabolism), adrafinil places additional load on the liver during conversion. Regular liver function tests are recommended with sustained use Hepatotoxicity risk: Rare but documented cases of elevated liver enzymes. Avoid in individuals with pre-existing liver conditions or heavy alcohol use Skin reactions: Rare risk of Stevens-Johnson syndrome and DRESS syndrome, shared with modafinil. Discontinue immediately if skin rash develops Cardiovascular: May increase heart rate and blood pressure modestly. Use with caution in individuals with cardiovascular conditions Drug interactions: Metabolised by CYP3A4. May interact with hormonal contraceptives, warfarin, and other CYP3A4 substrates. Consult your doctor if taking medications
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!